Medigene's Drug Veregen® receives market approval in Canada
10 Setembro 2013 - 2:30AM
Medigene AG / Medigene's Drug Veregen® receives market approval
in Canada . Ad hoc announcement according to § 15 WpHG. Processed
and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.
Martinsried/Munich, 10 September
2013. Medigene AG (MDG, Frankfurt, Prime Standard) announced
today that its drug Veregen® for the
treatment of genital warts has obtained market approval in Canada.
Market launch of Veregen® by Medigene's
partner Triton Pharma is scheduled to take place during the first
half of 2014.
Veregen® is already
being marketed in the USA (by Fougera), in Germany, Austria and
Switzerland (by Abbott), in Spain (by Bial), in Serbia (by
Pharmanova) as well as in the Netherlands (by Will-Pharma) and
approved in further countries. The launch of Veregen®
in several other countries is expected until the end of 2013.
Medigene has entered into numerous marketing partnerships for
Veregen® across
Europe, Asia, and America, and is planning to continue this global
licensing strategy to further leverage the product's market
potential.
About
Veregen®: Veregen®, a
topical treatment for external genital or perianal warts, contains
a concentrate of catechins with a complex defined composition
extracted from green tea leaves. In its current treatment
guidelines for sexually transmitted diseases, the US Center for
Disease Control and Prevention recommends Sinecatechins 15%
ointment (Veregen®) as a
possible option for treating genital warts. In addition,
Sinecatechins 10% & 15% ointment (Veregen®) has
been included in the current European guideline on the treatment of
genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Triton Pharma
Inc.: The Canadian Company Triton Pharma, founded in 2001,
specializes in the commercialization of prescription drugs in
gynecology (women's health), urology, and dermatology. With
proprietary and licensed products on the market, the company is
successfully positioning itself as the ideal partner for Companies
wishing to establish their products in Canada. Further information
can be obtained at: www.tritonpharma.ca.
Medigene AG
(Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene
focuses on clinical research and development of novel drugs against
cancer and autoimmune diseases. Medigene was the first German
biotech company to have revenues from marketed products, which are
distributed by partner companies. It has two drug candidates in
clinical trials, EndoTAG®-1 and
RhuDex®, and is
developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and Veregen® are registered trademarks of
Medigene AG. Polyphenon E® is a trademark of Mitsui Norin
Co., Ltd. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia
Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1728101
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Meridian Gold (NYSE:MDG)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
